ANIXA BIOSCIENCES INC Profit Margin 2010-2022 | ANIX

Current and historical gross margin, operating margin and net profit margin for ANIXA BIOSCIENCES INC (ANIX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. ANIXA BIOSCIENCES INC net profit margin as of October 31, 2022 is 0%.
ANIXA BIOSCIENCES INC Annual Profit Margins
ANIXA BIOSCIENCES INC Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.136B $0.001B
Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00